TNGX TANGO THERAPEUTICS INC

Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S. financial markets. The company does not intend to hold a conference call.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit .

Investors and Media:

Elizabeth Hickin





EN
29/10/2025

Underlying

TNGXTANGO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TANGO THERAPEUTICS INC

 PRESS RELEASE
Free
TNGX TANGO THERAPEUT...

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Hea...

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 1:30pm ET. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast wi...

21h / 19m 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.10
VCYT VERACYTE INC
MTH Meritage Homes ... ... (+14)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

VCYT VERACYTE INC
MTH MERITAGE HOMES CORPORATION
DHI D.R. HORTON INC.
COLM COLUMBIA SPORTSWEAR COMPANY
VFC V.F. CORPORATION
HBB HAMILTON BEACH BRANDS HOLDING COMPANY
TNDM TANDEM DIABETES CARE
QTRX QUANTERIX CORPORATION
WGO WINNEBAGO INDUSTRIES INC.
NRIX NURIX THERAPEUTICS
TNGX TANGO THERAPEUTICS INC
FTREV FORTREA HOLDINGS INC.
BBNX BETA BIONICS
SION SIONNA THERAPEUTICS INC
11/24/25 November 24, 2025 1 EN
 PRESS RELEASE
Free
TNGX TANGO THERAPEUT...

Tango Therapeutics to Participate in the 2025 Jefferies Global Healthc...

Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, November 19 at 4:30-4:55 PM GMT / 11:30-11:55am ET. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay ...

November 12, 2025 1 EN
 PRESS RELEASE
Free
TNGX TANGO THERAPEUT...

Tango Therapeutics Reports Third Quarter 2025 Financial Results and Pr...

Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights – Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months–  – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49% ORR and mPFS 9.1 months in histology selective cohort of multiple late line, difficult to treat cancers provide further evidence of strong activity – – $225 million in gross proceeds from October 2025 financing extends cash runway into 2028 – BOSTON, Nov. 04, 2025 (GLOBE NEW...

November 4, 2025 1 EN
 PRESS RELEASE
Free
TNGX TANGO THERAPEUT...

Tango Therapeutics to Report Third Quarter 2025 Financial Results on T...

Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of ...

October 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch